ArticleImmunity, inflammation and disease2026
Combination Treatment of IL-17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriatic arthritis (PsA) is a chronic inflammatory disease with complex pathophysiology. Despite advancements in biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), treatment responses remain suboptimal for many patients.
methodsWe present a case of a 35-year-old male with refractory PsA who achieved significant clinical improvement through combination therapy with ixekizumab (an IL-17 inhibitor) and upadacitinib (a JAK inhibitor), following inadequate responses to multiple monotherapies. A scoping review of the literature was conducted, analyzing studies on dual b/tsDMARD therapy in PsA.
resultsThe patient achieved rapid clinical improvement with complete resolution of articular symptoms, normalization of inflammatory markers, and significant metabolic improvements. The scoping review identified 16 studies, highlighting the potential of multi-target strategies while emphasizing safety concerns such as increased infection risks.
conclusionThis case and review underscore the promise of combination therapy in PsA while emphasizing the need for further research to optimize its use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.